Compare Ascendis Pharma A/S (ASND) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Ecolab Inc. — how do they compare? Ascendis Pharma A/S trades at $262.7 (market cap $17.74B), while Ecolab Inc. trades at $271.41 (market cap $77.20B). The key difference: Ecolab Inc. is far larger — about 4.4× Ascendis Pharma A/S's market cap, and Ecolab Inc. pays a 1.06% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ECL | |
|---|---|---|
Market Cap | $17.74B | $77.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $308.35 |
52-Week Low | $163.32 | $245.73 |
Enterprise Value | $18.11B | $85.95B |
Dividend Yield | — | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ECL trades at $274.31, up 0.47% on the day, with a bullish technical signal and strong analyst support. The company reported $16.08B in 2025 revenue, $2.08B net income, and maintains robust profitability with a 12.8% net margin and 22.31% ROE. Recent news highlights the $4.75B CoolIT acquisition, expanding its AI cooling portfolio, and a consistent dividend payout.
Outlook remains positive with a consensus price target of $327.43, implying 19% upside, though risks include rising costs and negative cash flow trends. Earnings growth and digital expansion are key catalysts, but investors should monitor execution on acquisitions and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
